Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $120.62 and last traded at $120.56, with a volume of 389028 shares changing hands. The stock had previously closed at $118.58.

A number of research analysts have recently issued reports on ALNY shares. Needham & Company LLC assumed coverage on shares of Alnylam Pharmaceuticals in a report on Thursday, November 21st. They set a “buy” rating and a $135.00 price objective for the company. ValuEngine downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Piper Jaffray Companies set a $145.00 price objective on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, September 10th. Cowen reissued a “buy” rating and issued a $120.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Finally, UBS Group raised their target price on Alnylam Pharmaceuticals from $95.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, September 4th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $114.58.

The business has a 50 day moving average price of $95.25 and a two-hundred day moving average price of $80.82. The stock has a market cap of $13.22 billion, a PE ratio of -15.98 and a beta of 2.46. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.22 and a current ratio of 5.38.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.92) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.17) by $0.25. The company had revenue of $70.06 million during the quarter, compared to the consensus estimate of $57.14 million. Alnylam Pharmaceuticals had a negative return on equity of 52.88% and a negative net margin of 485.73%. Alnylam Pharmaceuticals’s revenue was up 3284.5% on a year-over-year basis. During the same period last year, the business posted ($1.56) earnings per share. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -7.87 earnings per share for the current year.

In other news, COO Yvonne Greenstreet sold 8,404 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $105.00, for a total transaction of $882,420.00. Following the completion of the transaction, the chief operating officer now directly owns 4,070 shares of the company’s stock, valued at approximately $427,350. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Marsha Fanucci sold 75,000 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $100.00, for a total transaction of $7,500,000.00. Following the transaction, the director now directly owns 30,000 shares of the company’s stock, valued at $3,000,000. The disclosure for this sale can be found here. Insiders have sold a total of 206,773 shares of company stock worth $18,988,930 over the last quarter. Company insiders own 3.60% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Maverick Capital Ltd. increased its holdings in Alnylam Pharmaceuticals by 31.9% in the 2nd quarter. Maverick Capital Ltd. now owns 4,236,016 shares of the biopharmaceutical company’s stock worth $307,365,000 after acquiring an additional 1,025,629 shares during the last quarter. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 7.6% during the second quarter. Vanguard Group Inc. now owns 9,316,686 shares of the biopharmaceutical company’s stock worth $676,018,000 after purchasing an additional 657,595 shares during the period. Farallon Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 120.0% in the second quarter. Farallon Capital Management LLC now owns 1,100,000 shares of the biopharmaceutical company’s stock worth $79,816,000 after purchasing an additional 600,000 shares in the last quarter. Baillie Gifford & Co. increased its stake in shares of Alnylam Pharmaceuticals by 9.3% in the second quarter. Baillie Gifford & Co. now owns 6,213,470 shares of the biopharmaceutical company’s stock worth $450,850,000 after purchasing an additional 528,966 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $28,946,000. Institutional investors and hedge funds own 95.79% of the company’s stock.

About Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Article: Stop Order Uses For Individual Investors

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.